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Abstract
A significant proportion of women develop a recurrence following an initial urinary tract infection (UTI). In women with recurrent UTI,
the predictive value of asymptomatic bacteriuria (ASB) for the development of a subsequent UTI has not yet been established and it is
not known whether information from an asymptomatic sample is useful in guiding antimicrobial therapy. To address these questions, we
used data that originated from the ‘Non-antibiotic prophylaxis for recurrent urinary tract infections’ (NAPRUTI) study: two randomized
controlled trials on the prevention of recurrent UTI in non-hospitalized premenopausal and postmenopausal women (n = 445). During
15 months of follow-up, no difference was observed in the time to a subsequent UTI between women with and without ASB at baseline
(hazard ratio: 1.07, 95% CI 0.80–1.42). The antimicrobial susceptibility and pulsed-field gel-electrophoresis (PFGE) pattern of 50 Escheri-
chia coli strains causing a UTI were compared with those of the ASB strain isolated 1 month previously. The predictive values of the
susceptibility pattern of the ASB strain, based on resistance prevalence at baseline, were ‡76%, except in the case of nitrofurantoin-
and amoxicillin-clavulanic acid-resistance. Asymptomatic and symptomatic isolates had similar PFGE patterns in 70% (35/50) of the
patients. In the present study among women with recurrent UTI receiving prophylaxis, ASB was not predictive for the development of
a UTI. However, the susceptibility pattern of E. coli strains isolated in the month before a symptomatic E. coli UTI can be used to make
informed choices for empirical antibiotic treatment in this patient population.
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Approximately 50% of all women will experience a urinary
tract infection (UTI) during their lifetime [1] and 27 and 44%
develop a recurrence following an initial UTI within
6 months and 1 year, respectively [2,3].
In women who have had at least three episodes of UTI in
a period of 12 months, low-dose antibiotic prophylaxis has
proved to be effective in reducing the number of recur-
rences [4]. However, this regimen has the disadvantage that
it results in the development of antimicrobial resistance [5].
In addressing this antimicrobial resistance problem in
women with recurrent UTI (rUTI), the information that can
be derived from earlier periods of asymptomatic bacteriuria
(ASB) has not yet been investigated. ASB is a condition in
which uropathogens are isolated from a urinary sample while
the patient is not experiencing symptoms indicating a UTI
[6]. The relationship between ASB strains and strains that
cause a subsequent UTI has been studied in several popula-
tions, but has not been addressed in women with rUTI
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[7–10]. In this population the predictive value of ASB for the
development of a subsequent UTI has not been established,
nor has the question of whether the antibiotic susceptibility
pattern of a microorganism isolated from an ‘asymptomatic’
sample can be used to determine the optimal empirical anti-
microbial therapy for a subsequent UTI.
We have therefore investigated, in women with rUTI
receiving either antibiotic or non-antibiotic prophylaxis,
whether the presence of ASB predisposes to the development
of a UTI. Furthermore, we determined whether the Escherichi-
a coli ASB strain isolated in the month preceding an E. coli UTI
was predictive for the strain causing the UTI, by comparing
antimicrobial susceptibilities and pulsed-field gel-electrophore-
sis (PFGE) patterns of the bacteria isolated in both episodes.
Materials and Methods
Patients
We used data that originated from the ‘Non-antibiotic pro-
phylaxis for recurrent urinary tract infections’ (NAPRUTI)
study [5,11]. Briefly, this study consisted of two randomized
controlled multicentre trials comparing 12 months of pro-
phylaxis with cranberries (in premenopausal women) or lac-
tobacilli (in postmenopausal women) with trimethoprim/
sulfamethoxazole prophylaxis. Non-hospitalized women over
18 years who had experienced at least three symptomatic
UTIs in the year preceding enrolment were eligible for inclu-
sion. Patients were excluded when symptoms of UTI were
noted at baseline. Recruitment took place from January 2005
to August 2007.
Midstream urinary samples were collected monthly and
when symptoms of UTI were observed during 15 months of
follow-up. Dipslides (Uriline, 56508, Biomérieux, Plainview,
NY, USA) were prepared from all collected urinary samples
and sent to the microbiological laboratory of Maastricht
University Medical Centre for identification of the micro-
organisms and testing of the antimicrobial susceptibility.
If women had a history of functional or structural abnor-
malities of the urinary tract, of metabolic or hormonal
abnormalities, or of impaired host responses, UTIs experi-
enced during follow-up were classified as complicated. UTIs
from all other women were classified as uncomplicated.
This information was retrieved from the NAPRUTI baseline
questionnaire, which also included questions about the num-
ber of UTIs in the year preceding enrolment and the sexual
activity.
The study protocol was approved by the Medical Ethics
Committees of all participating centres, and participants pro-
vided written informed consent before inclusion.
Predictive value of ASB for the development of UTI
To investigate whether the presence of ASB was predictive
for the development of UTI, the participating women were
divided into two groups, based on the presence of ASB at
baseline. ASB was defined as having ‡105 CFU/mL) on the
baseline dipslide. A UTI was defined as the presence of self-
reported symptoms of a UTI together with the isolation of a
uropathogen (‡103 CFU/mL) [12]. Because not all patients
had sent a urine sample when they had symptoms of a UTI,
we used occurrence of a clinical recurrence as a secondary
endpoint, which was defined as the presence of self-reported
symptoms of UTI without microbiological confirmation [5].
Predictive value of ASB susceptibility and PFGE patterns
Patients were selected in whom the first UTI during the
study was caused by E. coli. From this group (n = 160),
the patients were identified in which E. coli was detected in
the urine specimen collected in the month preceding the
first E. coli UTI (UTI minus 1 sample, n = 76).
Using a random selection procedure, stratified for meno-
pausal status and for complicated versus uncomplicated UTI,
50 patients were chosen for the assessment of the antimicro-
bial susceptibility and PFGE patterns of their E. coli isolates. A
flow-chart of this selection procedure is given in Fig. 1.
Antimicrobial susceptibility testing
The microdilution method used for determining the anti-
microbial susceptibility of the E. coli isolates involved
Mueller–Hinton II cation-adjusted broth (Becton and
Dickinson Company, Sparks, MD, USA), an inoculum of
5 · 105 CFU/mL and overnight incubation at 35C. The MIC
plates with freeze-dried antimicrobial agents were provided
by MCS Diagnostics (Swalmen, the Netherlands). Methods
and susceptibility breakpoints were in accordance with the
EUCAST guidelines [13].
Pulsed-field gel-electrophoresis
PFGE was carried out using XbaI (New England Biolabs Inc.,
Beverley, MA, USA) and interpreted as previously described
[14,15].
Statistical analysis
For the comparison of two groups a Pearson’s chi-square
test was used for categorical variables and a Student’s t-test
or Mann–Whitney U-test was used for continuous variables.
The cumulative probability of being UTI-free during the
15 months of follow-up for women with and without ASB at
baseline was studied using Kaplan–Meier estimates, with the
log rank test for the comparison. Subsequently, Cox regres-
sion analyses were conducted, which included the following
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potential confounders: age (in years), number of UTIs in the
year preceding enrolment, sexual activity (yes/no), premeno-
pausal status (yes/no), received trimethoprim/sulfamethoxaz-
ole prophylaxis (yes/no) and the presence of complicating
host factors (yes/no).
To test for potential effect modification by menopausal
status or received intervention or uncomplicated versus
complicated UTI, interaction terms between these variables
and presence of ASB at baseline were included in the statisti-
cal models. As these terms were not statistically significant,
they were removed from the models and risk estimates
were calculated for all women together.
In comparing susceptibilities per antimicrobial agent,
asymptomatic and symptomatic strains were considered to
be similar when they differed by no more than one dilution
step. However, isolates were not considered similar when
one of them was classified as ‘susceptible’ and the other as
‘resistant’.
For each antimicrobial agent tested, positive and negative
predictive values (PPV and NPV, respectively) were calcu-
lated as described by Vellinga et al. [16]. Calculated PPVs and
NPVs are based on the prevalence of resistance of the E. coli
strains isolated at baseline. To assess the influence of tri-
methoprim/sulfamethoxazole prophylaxis, we recalculated
our PPVs and NPVs based on the prevalence of resistance of
E. coli strains isolated after 12 months of trimethoprim/sulfa-
methoxazole prophylaxis. PPV was the proportion of patients
who had an asymptomatic isolate resistant to an antibiotic, in
whom the subsequent symptomatic isolate was also resistant
to this antibiotic. NPV was the proportion of patients in
whom the asymptomatic isolate was susceptible to an antibi-
otic and the symptomatic isolate also.
SPSS 16.0 was used for statistical analyses and p <0.05
was considered statistically significant. For our power calcu-
lation we used the program STATA, version 12.0 [17,18].
Results
Patients and samples
A total of 207 premenopausal and 238 postmenopausal
women participated. The number of ASB and UTI episodes
experienced is given in Table 1.
Of 209 patients who experienced a UTI, 160 (77%) had
E. coli as the causative uropathogen. One month preceding
these E. coli UTIs, E. coli was isolated from 76 patients
(48%). The mean time interval between the isolation of
the included asymptomatic and subsequent symptomatic
E. coli strains was 15 days (95% CI 12–17 days). These
patients were stratified according to trial (premenopausal
(A) versus postmenopausal (B)) and complicated (C) versus
uncomplicated (U) status resulting in four groups, i.e. AC,
AU, BC and BU. Four out of five (80%) AC, 14/20 (70%)
AU, 16/26 (62%) BC and 16/25 (64%) BU patients were
selected randomly for susceptibility and PGFE analysis
(Fig. 1a,b).
(a) (b)
E. coli present 1 month prior to 
E. coli UTI (n = 15) (50%) 
Experienced an E. coli UTI 
(n = 30) (31%) 
Received TMP/SMX (n = 98) 
(47%) 
Experienced an E. coli UTI 
(n = 35) (32%) 
Received cranberries (n = 109) 
(53%) 
E. coli present 1 month prior 




E. coli UTI  
Received  NAPRUTI 
intervention (n = 207) 
Enrolment 
Randomly selected for PFGE 
(n = 8) (80%) 
Randomly selected for PFGE 
(n = 10) (67%) 
PFGE selected 
   Received lactobacilli (n = 123)   
(52%) 
Received TMP/SMX (n = 115) 
(48%) 
Received  NAPRUTI 
intervention (n = 238) 
Allocation
Experienced an E. coli UTI 
(n = 43) (37%) 
Experienced an E. coli UTI 
(n = 52) (42%) 
E. coli UTI 
     E. coli present 1 month prior 
to E. coli UTI (n = 25) (48%) 
E. coli present 1 month prior to 
E. coli UTI (n = 26) (60%) 
Asymptomatic 
bacteriuria 
Randomly selected for PFGE 
(n = 17) (68%) 
Randomly selected for PFGE 
(n = 15) (58%) 
PFGE selected
FIG. 1. Flow diagram showing the pulsed-field gel-electrophoresis (PFGE) and antimicrobial susceptibility selection procedure for premenopausal
women (a) and postmenopausal women (b). TMP/SMX, trimethoprim/sulfamethoxazole.
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Predictive value of ASB for the development of a UTI
When comparing the probability of being UTI-free during
15 months of follow-up between women with and without
ASB at baseline, no difference was found (43% versus 45%,
p >0.05) (Fig. 2). After inclusion of the confounding factors,
ASB at baseline was still not predictive (hazard ratio 1.07,
95% CI 0.80–1.42). When clinical recurrence was used as
the endpoint, outcomes changed only marginally (data not
shown). Considering the number of participants for whom
the ASB status was known at baseline (n = 433), the pro-
portion of patients without ASB at baseline (60%, 258/433)
and the probability of being UTI-free for women without
ASB at baseline (45%), we would have been able to detect,
at power >80% and a = 0.05, a hazard ratio of 1.5 for
developing a microbiologically confirmed UTI in the follow-
up period.
Predictive value of ASB susceptibility and PFGE patterns
Table 2 gives PPVs and NPVs of the ASB strains. When PPVs
and NPVs were based on the prevalence of resistance after
12 months of trimethoprim/sulfamethoxazole prophylaxis,
the NPVs of amoxicillin (67%), trimethoprim (24%) and tri-
methoprim/sulfamethoxazole (24%) decreased because of the
development of resistance to these agents. For amoxicillin-
clavulanic acid, 7/13 (54%) discordant pairs differed by only
one dilution step, but were classified as dissimilar because
the asymptomatic E. coli was resistant whereas the symptom-
atic E. coli was susceptible. PFGE patterns were similar in six
of these seven E. coli pairs (86%).
From the 50 randomly selected patients, PFGE-concordant
E. coli isolates were observed in 35 women (70%). Stratifica-
tion of results into the categories AC, AU, BC and BU
showed that, in all groups, over 60% of the E. coli pairs were
similar (75%, 79%, 63% and 69%, respectively, Fig. 3). Also,
no difference was observed between the prophylactic regi-
mens: 72% (trimethoprim/sulfamethoxazole) versus 68%
(non-antibiotics), p >0.05.
In two patients with concordant PFGE results, susceptibil-
ity patterns differed by more than one dilution step for
amoxicillin, trimethoprim and trimethoprim/sulfamethoxa-
zole. On the other hand, differing PFGE results were associ-
ated with similar susceptibility results in eight patients.
For patients with concordant PFGE patterns, the median
time between the UTI and the UTI minus 1 sample was
12 days (range 1–32). For discordant PFGE patterns, the
median time was 20 days (range 5–33, p <0.05).
Discussion
In women with rUTI receiving prophylaxis, the presence of
ASB was not found to be a predictor for the development of
a UTI during 15 months of follow-up. Nonetheless, anti-
microbial susceptibility and the PFGE pattern of asymptom-
atic E. coli strains, isolated within 1 month before an E. coli
TABLE 1. Asymptomatic bacteri-
uria and urinary tract infection epi-
sodes
Premenopausal
women (n = 207)
Postmenopausal
women (n = 238)
Total study
population (n = 445)
ASB at baselinea 62 (31) 113 (48) 175 (40)
ASB at any moment during studyb 170 (82) 219 (92) 389 (87)
UTIc at any moment during studyb 82 (40) 127 (53) 209 (47)
ASB, asymptomatic bacteriuria; UTI, urinary tract infection.
Numbers are n (%).
aBaseline dipslides were collected from 433/445 (97%) of the patients: 199/207 (96%) premenopausal and 234/238
(98%) postmenopausal women.
bStudy duration was 15 months.
cDefined as the presence of self-reported symptoms of UTI in combination with the isolation of a uropathogen
(‡103 CFU/mL).
FIG. 2. Kaplan–Meier curves for the cumulative probability of being
urinary tract infection (UTI) -free during the 15 months of follow-up,
for women with and without asymptomatic bacteriuria at baseline.
No difference was observed between the two groups (p >0.05).
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UTI, correlated well with these characteristics of the UTI-
causing strain. At least 90% of the patients had a susceptible
E. coli UTI strain when a susceptible asymptomatic E. coli was
isolated, and this applied to all antibiotics tested. Also for
resistant asymptomatic isolates high predictive values (‡75%)
were found, with the exception of amoxicillin-clavulanic acid
(34%). Seventy percent of the E. coli pairs had similar PFGE
patterns.
The strength of this study was the comparison on an indi-
vidual level of ASB and UTI strains with regard to antimicro-
bial susceptibility and PFGE pattern. Furthermore, to the
best of our knowledge this was the first study that addressed
the predictive value of strains causing ASB in women with
rUTI. In addition, this was a sub-analysis of data that were
acquired prospectively.
A limitation was that in the NAPRUTI study women did
not always send a urine sample when experiencing symptoms
of a UTI, so the number of microbiologically confirmed UTIs
may be underestimated. However, the influence on the pres-
ent analyses seems limited because using clinical recurrence
as the endpoint did not alter our results. Also, our study
population could be seen as heterogeneous by the inclusion
of both premenopausal and postmenopausal women, with
differing risk factors and clinical parameters. However, inter-
action testing between ASB and menopausal status revealed
no significant results, indicating that the association between
ASB and UTI was similar in both premenopausal and post-
menopausal women. This justifies the combined analysis of
these groups in the present study. Furthermore, 40% of all
women had ASB at baseline, and almost all experienced an
episode of ASB during the study period. Such high levels of
ASB have only been observed in specific patient populations,
such as catheterized patients and elderly people in long-term
care facilities [19,20]. In the general population, ASB is found
in 1–5% of women, and can increase to 8.6% in postmeno-
pausal women [6,19]. The high prevalence in the present
study could partly be explained by the use of a single-voided
specimen to indicate ASB, instead of two consecutive sam-
TABLE 2. Positive and negative
predictive values of the resistance
pattern of an asymptomatic bacte-
riuria strain isolated in the month
preceding the symptomatic urinary
tract infection
Prevalence of
resistance (%)a PPVb 95% CI NPVc 95% CI
Amoxicillin 35 83 60–94 90 81–95
Amoxicillin-clavulanic acid 15 34 21–49 94 86–98
Trimethoprim 34 76 54–89 94 86–98
Trimethoprim/
sulfamethoxazole
33 76 53–89 94 86–98
Norfloxacin 14 100 96–100 97 90–99
Ciprofloxacin 13 100 96–100 97 90–99
Nitrofurantoin 0 NAd NAd NAd NAd
ASB, asymptomatic bacteriuria; 95% CI, 95% confidence interval; NPV, negative predictive value; PPV, positive predic-
tive value; UTI, urinary tract infection.
aPrevalence of resistance is based on susceptibility data from Escherichia coli strains isolated at baseline.
bProportion of patients who had an asymptomatic isolate resistant to this antibiotic in whom the subsequent symp-
tomatic isolate was also resistant to this antibiotic.
cProportion of patients in whom the asymptomatic isolate was susceptible to this antibiotic and the symptomatic iso-
late was also susceptible to this antibiotic.
dNot applicable (NA) because no nitrofurantoin-resistant E. coli was found at baseline.
1 2 3 4 5 6 7 8 
FIG. 3. Example of pulsed-field gel-electrophoresis (PFGE) patterns.
The patterns of 18 Escherichia coli strains, obtained from eight
patients, are shown. Isolates belonging to one patient are indicated
by horizontal lines above the PFGE lanes. For each patient, the first
lane represents the asymptomatic strain, whereas the second (and
third) lane(s) represent(s) the symptomatic strain(s). Two E. coli
pairs had different PFGE patterns (patients 2 and 4). In patients 2
and 8, PFGE was performed on two symptomatic E. coli strains (lanes
4 and 5, and lanes 17 and 18, respectively) with different colony
morphology on the blood agar plate, but a similar PFGE pattern.
E88 Clinical Microbiology and Infection, Volume 18 Number 4, April 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E84–E90
ples as formulated in the original definition [20]. The use of
a single specimen is now accepted as a more practical and
adequate alternative [21]. However, it seems that ASB is
more common in women with rUTI than in women without
such a history. Finally, no placebo group was included in the
NAPRUTI study, making our results mainly applicable to
women with rUTI receiving prophylaxis. With long-term
prophylaxis as the standard treatment for women with
rUTI, this limits the external validity of our findings only
marginally.
The predictive value of ASB has been previously evaluated
in a prospective cohort study, which revealed a marginal
association between UTI and ASB (hazard ratio 1.8, 95% CI
0.9–3.5) [9]. Another prospective study among premenopau-
sal women showed that 8% of women with ASB developed a
UTI within 1 week compared with 1% without ASB [10].
However, the women included in these prospective studies
had had no history of recurrent UTI, making a comparison
with our study difficult. The predictive value of ASB needs
further evaluation in specific subgroups; for example, renal
transplant patients, in whom ASB has been associated with a
higher incidence of pyelonephritis [22].
The negative predictive value of ASB strains, in terms of
antimicrobial susceptibility, was diminished after long-term
trimethoprim/sulfamethoxazole prophylaxis, leading to low
predictive values of ASB E. coli initially susceptible to amoxi-
cillin, trimethoprim and trimethoprim/sulfamethoxazole (67%,
24% and 24%, respectively). The high prevalence of resis-
tance to these agents was expected because their resistance
genes are plasmid linked [23]. However, the clinical rele-
vance of these low NPVs is limited because these agents will
not be considered as appropriate treatment options in
women receiving trimethoprim/sulfamethoxazole prophylaxis.
The value of antimicrobial susceptibility results from previ-
ously obtained isolates has also been studied by Vellinga
et al. [16]. When the interval between two UTIs was no
more than 3 months, they reported NPVs ranging from 78
to 98% and low PPVs for amoxicillin-clavulanic acid (55%)
and nitrofurantoin (20%), similar to our observations. Our
observed relatively low PPV for amoxicillin-clavulanic acid
was mainly the result of the susceptibility breakpoint used,
as most discordant E. coli pairs differed by only one MIC
dilution step. All but one of the pairs concerned showed
similar PFGE patterns, so especially in the case of amoxicil-
lin-clavulanic acid, the use of quantitative susceptibility data is
more appropriate than the susceptibility breakpoint. Vellinga
et al. explained the low PPV of nitrofurantoin by a relatively
quick decay of resistance to this agent when such resistance
is found. This is in accordance with the reported low preva-
lence of resistance of E. coli to nitrofurantoin as, for exam-
ple, shown by the ARESC study in which nitrofurantoin
resistance did not exceed 5% [24]. The absence of resistance
to nitrofurantoin observed among our E. coli is in line with
these results. Hence, the recently recorded E. coli suscepti-
bility results need to be considered in clinical practice,
thereby leading to a more patient-specific approach to the
treatment of women with rUTI. This can primarily be applied
to patients in the hospital setting, where urinary samples are
often requested by treating physicians. General practitioners
can apply these findings to patients shortly after hospital dis-
charge.
Of our asymptomatic and symptomatic E. coli pairs, 70%
had similar PFGE patterns. A similar rate (68%) was found by
Russo et al. [25]. During a 3-month follow-up, Czaja et al.
[26] reported a same-strain bacteriuria of 7% 14 days before
a UTI, that gradually increased to 69% 1 day before the UTI.
Czaja et al. included women aged 18–49 years who had had
a history of at least one UTI during the past year, whereas
the NAPRUTI inclusion criterion was a minimum of three
UTIs. The different patient characteristics of the two study
populations might account for the different results [27]. We
found a shorter time interval between the two sampling
moments for PFGE-concordant E. coli strains compared with
PFGE-discordant pairs, which is in accordance with the time-
dependent trend reported by Czaja et al. [26].
Two E. coli pairs had similar PFGE patterns, but differed in
susceptibility pattern. This might be because of the presence
of integrons encoding for b-lactam, trimethoprim and sulfa-
methoxazole resistance, because integrons are too small to
be detected by PFGE [28]. The PFGE patterns reflect more
than the antimicrobial susceptibility alone and this could
explain our finding that eight patients had similar antimicro-
bial susceptibility results but different PFGE patterns [15].
In conclusion, the presence of ASB is not predictive for
the development of UTI in women with rUTI using prophy-
laxis, but the antimicrobial susceptibility of isolates from
asymptomatic urinary samples can be used to guide antibiotic
therapy when a UTI develops within 1 month.
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